Currently, most physicians rely on a number of medications[1] in order to treat Alzheimer’s.  These work by using two different molecules to boost the brain’s ability to transmit information from one brain cell to another.

One class of medications is known as cholinesterase inhibitors.  Alzheimer’s affects brain function by breaking down neurotransmitters, the brain cells that communicate information from cell to another.  First approved by the FDA to treat Alzheimer’s in 1996, cholinesterase inhibitors work to slow down the destructions of these neurotransmitters by blocking certain chemical signals.

The other class of medications is the newer class, approved by the FDA in 2003.  Known as NMDA (N-methyl-D-aspartate) receptor antagonists, these work by interfering with the function of glutamate, one of the key types of neurotransmitters in the brain, at some of its receptors.  NMDA receptor antagonists block additional calcium from entering the cells.  Patients with Alzheimer’s often have glutamate toxicity, increasing cellular calcium and damaging the cells, thus progressing of the disease.

Currently, the five medications approved by the FDA to treat Alzheimer’s are:

  • Donepezil (Aricept) – Cholinesterase inhibitor.
  • Galantamine (Razadyne) – Cholinesterase inhibitor.
  • Memantine (Namenda) – NMDA.
  • Rivastigmine (Exelon) – Cholinesterase inhibitor.
  • Donepezil + Memantine (Namzaric) – NMDA + Cholinesterase inhibitor.

Dr. Dale Bredesen has shown for the first time that cognitive decline can be reversed.

In 2014, Dr. Bredesen published a paper[2] that detailed how dietary and multi-factorial risk assessment screening techniques were addressed by a comprehensive therapeutic program—for the first time, patients with cognitive decline associated with Alzheimer’s disease or pre-Alzheimer’s (SCI, which is subjective cognitive impairment, or MCI, which is mild cognitive impairment) actually reversed their cognitive decline. Most importantly, they sustained their improvement.  A second paper published in 2016[3] focused on metabolic enhancement techniques that helped reverse cognitive decline in Alzheimer’s patients, a key component of the technology now known as the ReCODE program.

Using a computer-based algorithm to assess the results of a set of blood tests, the ReCODE program devises an optimized, personalized treatment program that combines specific nutritional approaches, brain training, specific supplements, lifestyle changes, and other therapeutics to treat and reverse the symptoms of Alzheimer’s.